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DHPLC = denaturing high-performance liquid chromatography; LOH = loss of heterozygosity; PCR = polymerase chain reaction; SSCP = single-
stranded conformation polymorphism.
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Abstract
In order to explore the possible role of E-cadherin in familial cancer, 19 familial breast cancer patients,
whose tumours demonstrated loss of heterozygosity (LOH) at the E-cadherin locus, were screened for
germline mutations. No pathogenic germline alterations were detected in these individuals. However, a
somatic mutation was found (49-2A®C) in one of the tumours. This tumour showed a pattern of both
ductal and lobular histology. Another 10 families with cases of breast, gastric and colon cancer were
also screened for germline mutations, and no mutations were found. A missense mutation in exon 12 of
E-cadherin (1774G®A; Ala592Thr) was previously found in one family with diffuse gastric cancer, and
colon and breast cancer. An allelic association study was performed to determine whether the
Ala592Thr alteration predisposes to breast cancer. In total, we studied 484 familial breast cancer
patients, 614 sporadic breast cancer patients and 497 control individuals. The frequencies of this
alteration were similar in these groups. However, a correlation between the Ala592Thr alteration and
ductal comedo-type tumour was seen. These results, together with previously reported studies,
indicate that germline mutations and, more commonly, somatic mutations in E-cadherin may have an
influence on the behaviour of the tumours, rather than predispose to breast cancer.
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Synopsis
Introduction: E-cadherin (CDH1) is expressed on the cell
surface in most epithelial tissues [1,2], and evidence is
rapidly accumulating that the mammalian E-cadherin gene
product plays a role in epithelial tumourigenesis [3]. Germline
mutations in E-cadherin have been described in families with
early-onset diffuse gastric cancer, and loss of function of this
gene has been implicated in the pathogenesis of early-onset
colorectal and breast cancers. Despite the fact that E-
cadherin expression is decreased in 50% of invasive ductal
carcinoma [4], mutations in the coding sequence of E-
cadherin have not been observed in this type of breast
cancer [5,6]. The role of E-cadherin mutation in development
of hereditary gastric cancer has been shown, but its role in
predisposing to breast cancer is still unproved. In order to
further explore the involvement of E-cadherin in breast
cancer, we examined all 16 exons of E-cadherin in 31 familial
breast cancer patients, in whom BRCA1 and BRCA2 had
been excluded as predisposing genes [7–9].
In a previous study of a family with diffuse gastric cancer
(Fig. 1a) (Salahshor S, et al, manuscript submitted), we
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(Print ISSN 1465-5411; Online ISSN 1465-542X)identified an E-cadherin germline mutation that cosegregated
with the disease. This missense mutation in exon 12
(Ala592Thr) was also detected in the index patient’s mother,
who had ductal breast cancer. In an attempt to clarify a
possible role for the Ala592Thr alteration in predisposing to
breast cancer, we screened for this specific alteration in
different series of breast cancer patients and control
individuals. In total, 1328 patients with sporadic or familial
breast cancer and 497 control individuals were analyzed for
this specific alteration.
Materials and methods: Nineteen probands with familial breast
cancer who demonstrated LOH at chromosome 16q, and 12
patients from 10 families with breast, gastric and colorectal
cancers were screened for germline mutations in the coding
sequences of E-cadherin. Nine tumours from the 19 breast
cancer cases were also screened for somatic mutations. The
frequencies of the 1774G®A variant (Ala592Thr) were
determined in DNA extracted from the blood of 358 unrelated
probands with familial breast cancer, 214 unrelated early-onset
breast cancer patients (age of onset <41 years), 126 unrelated
BRCA1 or BRCA2 carriers, and 604 unselected breast cancer
patients and 497 control individuals, who were considered to
represent the general population in Sweden and Norway.
Two markers D16S7/p79-2-23 and APRT/HUAP15, which
both map to 16q24.3, were used to identify LOH, as in a
previous study of allelic loss at 16q in familial tumours [10].
Single-stranded conformation polymorphism (SSCP) and
denaturing high-performance liquid chromotography (DHPLC;
Transgenomic, Santa Clara, CA, USA) were used to screen 16
exons of the E-cadherin gene for the presence of alterations
(Table 1). We used the same primers as described by Berx et
al [5] and Salahshor et al (manuscript submitted), but with
some modification. Samples that exhibited aberrant bands on
the SSCP gel or an altered DHPLC pattern were sequenced
by reamplifying the corresponding exon. Sequencing was
performed either manually using the ThermoSequensase
(Amersham Pharmacia Biotech, Uppsala, Sweden) kit, or by
377 ABI automated sequencer using the Taq-Cycle
sequencing BigDye Terminator kit (Applied Biosystems Inc
ABI, Stockholm, Sweden), according to conditions
recommended by the manufacturers. The Ala592Thr variant
frequency was detected using specific polymerase chain
reaction (PCR)–restriction fragment length polymorphism tests
(Salahshor S, et al, manuscript submitted).
Results: No pathogenic mutations were identified in the 12
patients from families with documented breast, gastric or colon
cancer. We also searched for germline alterations in 19
individuals with familial breast cancer who showed LOH at the
E-cadherin locus in their tumours. Nine tumours from these 19
patients were also tested for somatic alterations in the E-
cadherin gene. One somatic mutation (49-2A®C) was found
in one of the lobular cancer cases (Fig. 2). One previously
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Figure 1
Pedigrees of the four families with Ala592Thr missense alteration. BR, breast cancer; GA, gastric cancer; OV, ovarian cancer; GI, gastrointestinal
cancer; AD, colonic adenomas; Endo, endometrial cancer; M, positive for the Ala592Thr variant; N, wild-type E-cadherin.reported common polymorphism in E-cadherin [11] was found
in exon 13 at codon 692 (GCC®GCT).
In a previous study in one family with familial diffuse gastric
cancer and colon cancer (Fig. 1a) (Salahshor S, et al, manuscript
submitted), we found a germline missense mutation in exon 12
(Ala592Thr) of E-cadherin. This alteration cosegregated with
diffuse gastric cancer and colorectal cancer in this family,
although the penetrance was not complete. The alteration was
present in the index patient’s mother, who had ductal breast
cancer of comedo type at the age of 65 years (Fig. 1a, II:12). In
order to investigate whether this alteration was associated with
an increased risk for breast cancer, we used a specific restriction
enzyme digestion/PCR test to detect the variant, in an allelic
association study in familial and sporadic breast cancer cases,
as well as control samples that represented the general
population. We found the mutation in two out of 358 (0.56%)
non-BRCA1/BRCA2 carrier women with familial breast cancer
(families 205 and 2027). In family 205 (Fig. 1b), one woman with
ductal comedo-type breast cancer at age 75 years had the
Ala592Thr variant. The other available case from this family
(Figure 1b, II:2) tested negative, and the histology report was not
available. In family 2027 (Fig. 1c), one woman with a breast
cancer of ductal comedo type at age 37 years showed the
Ala592Thr variant. Her two sisters, who had breast cancer at
ages 45 and 51 years, did not. One of the sisters had lobular
breast cancer, whereas the histopathological information from
the third case was unavailable for study. Because the variant did
not segregate with the disease, it is not likely that this alteration
predisposes to breast cancer in either of these two families.
We also screened 126 BRCA1 or BRCA2 carriers from
different families, and found the mutation in one breast cancer
patient (family 4056) with a BRCA1 germline mutation
(delC2594). It was possible to obtain a sample from her sister
who also carried the BRCA1 mutation, and she was found to
share the Ala592Thr variant (Fig. 1d). Both tumours were of
ductal comedo type. Because both of these tumours were
caused by a germline BRCA1 mutation, the E-cadherin variant
was not likely to have predisposed to breast cancer. Among
the 604 sporadic breast cancer cases, five were found to carry
the Ala592Thr alteration (0.83%; Table 2). One of the tumours
was of lobular type, and the other four were of ductal type. One
of the ductal tumours was of comedo type, and the tumour type
of the other three was not known. Four cases with Ala592Thr
alteration were also found among the 497 control individuals
(0.80%). The alteration was not found among any of the 214
early-onset breast cancer patients.
Discussion: So far, E-cadherin germline mutations have been
reported in 17 diffuse gastric cancer families [12–16]. The
frequency of E-cadherin germline mutations in breast cancer
reported thus far is low [17,18]. Mutations reported in
E-cadherin in lobular breast cancer patients are in most cases
tumour restricted, and not germline alterations [5,19]. In the
present study, we did not find any pathogenic alteration in 10
families that included patients with breast, gastric or colon
cancer. We conclude that, although germline E-cadherin
Available online http://breast-cancer-research.com/content/3/3/199
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Table 1
PCR and DHPLC conditions for the mutational analysis of
E-cadherin
Annealing Amplicon DHPLC 
temperature length  temperature 
Exon no (°C) (bp) (°C)
1 70 285 66
2 55 377 62
3 60 352 58, 61
4 60 351 60
5 60 398 58
6 58 246 59
7 60 329 60, 62, 64
8 58 225 59, 62
9 55 252 59
10 55 309 58
11 60 243 61
12 60 326 59, 61
13 58 297 58
14 60 206 61
15 60 244 58
16 60 318 59
Figure 2
The 3¢ splice site alteration in the E-cadherin gene (49-2A®C) in
tumor M279.Introduction
E-cadherin (CDH1) is expressed on the cell surface in
most epithelial tissues [1,2], and evidence is rapidly accu-
mulating that the mammalian E-cadherin gene product
plays a role in epithelial tumourigenesis [3]. Loss of func-
tion in E-cadherin and/or other collaborating proteins
contributes to increased proliferation, invasion and
metastasis in many malignant epithelial tumours [22,23].
Mutations in E-cadherin, which encodes a transmem-
brane protein, have been described in cancers of the
endometrium and ovary [11], signet ring cell carcinoma of
the stomach [24,25], the diffuse sclerosing variant of
papillary thyroid carcinoma [26], invasive lobular breast
cancer [5,19,27,28], and diffuse and mixed gastric
cancer [24,28–30]. E-cadherin germline mutations have
been found in early-onset hereditary diffuse gastric
cancer [12,14,16], and such mutations have even been
implicated as risk factors for early-onset breast and colon
cancers [13,15]. Inactivating mutations and decreased
expression of E-cadherin have been reported in invasive
lobular breast carcinomas [5,19], which demonstrate
involvement of E-cadherin alteration in sporadic lobular
breast cancer. Lobular carcinoma in situ is known to be a
risk factor for breast cancer, but thus far constitutional E-
cadherin mutations have not been identified in patients
with lobular carcinoma in situ [18]. In sporadic breast
cancer, a correlation between loss of E-cadherin expres-
sion and metastatic behaviour has been reported
[4,31–33]. Despite the fact that E-cadherin expression is
decreased in 50% of invasive ductal carcinomas [4],
mutations in the coding sequence of E-cadherin have not
been observed in this type of breast cancer [5,6].
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mutations are sometimes found in familial gastric and colon
cancer, they are not frequently involved in families in which
gastric cancer appears to segregate as a part of an inherited
predisposition to primary breast cancer.
The frequency of Ala592Thr alteration, which was first identified
in one family with familial diffuse gastric cancer plus one case of
colon and one case of breast cancer (Fig. 1a), was similar in the
various groups studied here (Table 2). This finding does not
support an effect of this alteration in predisposing to breast
cancer in general. Thus, available data indicate that germline E-
cadherin mutations do not constitute a major risk factor for
breast cancer. However, other studies have indicated that
somatic alterations could have an impact on the phenotype in
lobular breast cancer. The fact that many tumours with the
alteration (Ala592Thr) in the present study were of the ductal
comedo type may indicate a genetic basis for the phenotypic
divergence caused by this germline E-cadherin alteration.
Although lobular breast carcinoma and ductal breast carcinoma
of comedo type are different from each other histologically,
neither of these cancers are associated with good prognosis.
However, individual prognosis with breast cancer is assessed
mainly by grading rather than by histological type [20,21].
In summary, the present study, together with previously
reported data, suggests that a germline mutation in E-cadherin
is not a major risk factor for breast cancer. However, germline,
and more often somatic mutations in this gene could have an
impact on phenotypic divergence and prognosis, including
growth pattern of the tumours, such as in lobular and perhaps
ductal comedo-type breast cancer. In addition, other genetic
alterations or epigenetic changes in the E-cadherin gene may
have an impact on the metastatic behaviour of the cancer cells,
and thereby on the clinical outcome.
Table 2
Frequency of Ala592Thr variant in various populations of breast cancer patients and control population
No of families/ Frequency of 
Screened population no of cases Ala592Thr variant Case id Histopathology
Familial breast cancer
Non-BRCA1/BRCA2 mutation carrier 358 0.56% 311-89D Ductal comedo
AL-155 Ductal comedo
BRCA1/BRCA2 carrier 126 0.79% BR-115 Ductal comedo
BR-119 Ductal comedo
Sporadic breast cancer
Early-onset breast cancer 214 –
Unselected breast cancer 604 0.83% 17-S Lobular
MB-181 Ductal comedo
MB-483 Ductal
ULL-17 Ductal
ULL-284 Ductal
Control population 495 0.80%
Full articleA role of E-cadherin mutation in development of hereditary
gastric cancer has been shown, but its role in predispos-
ing to breast cancer is still unproved. In order to further
explore the involvement of E-cadherin in breast cancer, we
examined all 16 exons of E-cadherin in 31 familial breast
cancer patients in whom involvement of BRCA1 and
BRCA2 had been excluded [7–9]. Twelve of these breast
cancer patients (from 10 families) had, besides a family
history of breast cancer, a family history of gastric or
colorectal cancer. The remaining 19 familial breast cancer
patients were identified as having LOH at 16q in their
tumour [34]. LOH at 16q occurs frequently in sporadic
[35] and in familial breast cancer [10]. It has also been
shown to correlate with distant metastasis [34,36]. In the
familial breast cancer patients in whom LOH at 16q was
identified, E-cadherin was suggested to be a candidate
predisposing tumour suppressor gene [34], and the aim of
the present study was to elucidate this relation.
In a previous study in a family with diffuse gastric and
colon cancer (Salahshor S, et al, manuscript submitted),
we found an E-cadherin germline mutation that cosegre-
gated with the disease. This missense mutation in exon 12
(Ala592Thr) was also detected in the index patient’s
mother, who had ductal breast cancer. In an attempt to
clarify a possible role of the Ala592Thr alteration in predis-
posing to breast cancer, we screened for this specific
alteration in different series of breast cancer patients and
control individuals. In total, 1328 patients with sporadic or
familial breast cancer and 497 control individuals were
tested for this specific alteration.
Materials and methods
Cases
Cases screened for mutations in the E-cadherin gene
Nineteen women with breast cancer who exhibited LOH
at 16q were included in the present study. All of these
index patients had a positive family history (more than one
first- or second-degree relative with breast cancer). Ten
of the 19 cases were of ductal histology, one case was
both ductal and lobular, two cases were lobular only and
one case was medullar. For five other cases information
regarding histology was not available [10,34]. Nine
tumours (four ductal, two lobular, one with both ductal
and lobular, and two cases with unknown histology) from
these 19 patients were also tested for somatic mutations
in E-cadherin.
In order to examine whether germline mutations in E-cad-
herin are involved in familial breast, gastric and colon
cancer, 12 patients from 10 such families were also
included in the present study. Six of those 12 cases had
breast cancer, five had colon cancer, and one was
affected with both breast and colon cancer. The histology
of the breast and gastric cancers in this group was not
available for study.
Individuals genotyped for the Ala592Thr variant 
The frequencies of Ala592Thr variant were determined in
DNA extracted from blood of 358 probands with familial
breast cancer, 214 unrelated early-onset breast cancer
patients (age of onset <41 years), 126 unrelated BRCA1
or  BRCA2 carriers, and 604 unselected breast cancer
patients from consecutive series. In addition 497 control
patients were genotyped, who were considered to repre-
sent the general populations of Sweden and Norway. The
Norwegian control individuals (a total of 244) included 177
healthy female individuals obtained through the Norwegian
Population Registry as a population-based series of
women aged 20–44 years from the Oslo area, and 67
healthy women (aged 55–79 years) from a mammographic
screening programme from Bergen area. The Swedish
control individuals (a total of 253) were healthy relatives of
individuals who were counseled at the Karolinska hospital.
In the present study, ‘familial breast cancer cases’ are
defined as patients with more than one first- or second-
degree relative with breast cancer, regardless of age. All
familial cases had already been tested for germline muta-
tions in the BRCA1 and BRCA2 genes.
Determination of loss of heterozygosity
In the previous study of allelic loss at 16q in familial
tumours [10] the two markers D16S7/p79-2-23 and
APRT/HUAP15, which map to 16q24.3, were used. Both
markers are distal to E-cadherin.
Mutation analysis
Polymerase chain reaction/single-stranded conformation
polymorphism
SSCP was used to screen 16 exons of the E-cadherin gene
for the presence of alterations, as described by Berx et al
[5] and Salahshor et al (manuscript submitted), but with
some modification.
Denaturing high-performance liquid chromatography
DHPLC was carried out on automated instrumentation
equipped with a DNA-separation column (Wave® system;
Transgenomic). PCR and Taq Gold™ enzyme (Applied
Biosystems Inc ABI) were used to amplify all 16 exons of
E-cadherin (96°C, 15 min; 94°C, 30 s; 50–70°C, 30 s;
72°C, 45 s for 30 cycles; 72°C, 2 min). The primers used
were as described previously [5] (Salahshor S, et al, man-
uscript submitted). Heteroduplexes and homoduplexes
were formed when the PCR products were hybridized by
heating to 95°C (for 5 min) and cooling slowly (by
1.5°C/min, 47 cycles). Five microlitres of each PCR
product were then analyzed using the Wave® system
(Transgenomic). DNA was eluted with a mixture of
buffer A (0.1 mol/l triethylamine acetate) and buffer B
(0.1 mol/l triethylamine acetate, 25% acetonitrile) at a flow
rate of 0.9 ml/min. The mobile-phase gradients and the
temperatures for running each exon were suggested by
Available online http://breast-cancer-research.com/content/3/3/199
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sequence contents. The temperatures at which PCR prod-
ucts were analyzed are given in Table 1. The results were
analyzed using HSM7000 software (Transgenomic).
Sequencing
Samples with an aberrant band on the SSCP gel or an
altered DHPLC pattern were sequenced by reamplifying
the corresponding exon. Sequencing was performed
either manually using the ThermoSequensase (Amersham
Corp) kit, or with the 377 ABI automated sequencer using
the Taq-Cycle sequencing BigDye Terminator kit (Applied
Biosystems Inc) according to the standard conditions rec-
ommended by the manufacturer.
Restriction enzyme digestion
The Ala592Thr variant was detected using a specific
PCR–restriction fragment length polymorphism test. In
short, two pairs of primers, E-CAD12F (TGTCTGATGT-
GAATGACAGC) and E-CAD12R (TGCTGTGAAGGGA-
GATGTAT) were used for amplification of nucleotides
1574–1884 of E-cadherin (based on GenBank accession
number Z13009). The forward primer generates an in vitro
mutation at nucleotide 1772 (A®G), leading to an Hha I
restriction site in the PCR product. If the endogenous
mutation 1774 (G®A) is present, then the Hha I restric-
tion endonuclease site is lost. Mutated samples are distin-
guished from normal samples by a 20-bp longer
uncleaved exon 12 fragment on agarose gels (Salahshor
S, et al, manuscript submitted).
Results
Screening for E-cadherin germline alterations in
familial breast cancer
The entire coding region of the E-cadherin gene was
studied, including splice sites, using PCR/SSCP and
sequencing in 10 families with histories of breast, gastric
and colon cancer. No pathogenic germline mutation was
identified in any of the individuals screened.
Negative results were also obtained by screening for
germline alterations in 19 individuals with familial breast
cancer who exhibited LOH at the E-cadherin locus in their
tumours. We also searched for somatic alterations in nine
of these 19 cases in whom tumours were available for
analysis using Wave® (Transgenomic), an HLPC-based
nucleic acid fragment analysis system. One somatic muta-
tion in an exon 2 splicing site (49–2A®C) was detected
in the tumour that was of both ductal and lobular histology
(Fig. 2). Clinical outcomes of these 19 patients were avail-
able, with 5–12 years of follow up. The two lobular breast
cancer patients had both developed distant metastases,
whereas distant metastases had developed in five out of
10 patients with ductal breast cancer. The patient with
ductal–lobular histology and the mutation did not have
distant metastasis 8 years after surgery. One previously
reported common polymorphism in E-cadherin [11] was
found in exon 13 at codon 692 (GCC®GCT).
The frequency of the Ala592Tyr missense alteration
In a previous study of one family (family 26) with familial
colon and gastric cancer (Fig. 1a) (Salahshor S, et al,
manuscript submitted), we identified a germline missense
alteration in exon 12 (Ala592Thr) of E-cadherin. This alter-
ation cosegregated with diffuse gastric cancer and col-
orectal cancer in this family, although the penetrance was
not complete. The alteration was present in the index
patient’s mother, who had ductal breast cancer of comedo
type at age 65 years (Figure 1a, II:12). In order to investi-
gate whether this alteration was associated with an
increased breast cancer risk we used a specific restriction
enzyme digestion/PCR test to detect the variant, in an
allelic association study of familial and sporadic breast
cancer patients as well as control individuals who were
considered to represent the general population.
We found the mutation in two out of 358 (0.56%) non-
BRCA1/BRCA2 carrier women with familial breast cancer
(families 205 and 2027). In family 205 (Fig. 1b), one
woman with ductal comedo-type breast cancer at age
75 years had the Ala592Thr variant. The other available
case from this family (Fig. 1b, II:2) tested negative, and the
histology report was not available. In family 2027 (Fig. 1c),
one woman with a breast cancer of ductal comedo type at
age 37 years exhibited the Ala592Thr variant, whereas her
two sisters with breast cancer at ages 45 and 51 years
did not. One of the sisters had lobular breast cancer, but
histopathological information on the third case was not
available. Because the variant did not segregate with the
disease, it is not likely that this alteration predisposes to
breast cancer in either of these two families.
We also screened 126 BRCA1 or BRCA2 carriers from
different families, and identified the mutation in one patient
with breast cancer (family 4056) with a BRCA1 germline
mutation (2594delC). It was possible to obtain a sample
from her sister who also carried the BRCA1 mutation, and
she was found to share the Ala592Thr variant also
(Fig. 1d). Both tumours were of ductal comedo type.
Because both of these tumours were caused by a
germline  BRCA1 mutation, the E-cadherin variant was not
likely to have predisposed to breast cancer.
Among the 604 sporadic breast cancer patients, five were
found to carry the Ala592Thr alteration (0.83%; Table 2).
One of these was of lobular type and the other four were
of ductal type. One of the ductal tumours was of comedo
type, but it was not known for the other three whether they
were of comedo type. Four cases with Ala592Thr alter-
ation were also found among the 497 control patients
(0.80%). The alteration was not found among any of the
214 early-onset breast cancer patients.
Breast Cancer Research    Vol 3 No 3 Salahshor et alDiscussion
E-cadherin germline mutations in familial breast cancer
Thus far, E-cadherin germline mutations have been
reported in 17 diffuse gastric cancer families [12–16]. The
high rate of mutations found in the Maori families probably
reflects the criteria used for selection of the families. In
these families at least three first-degree relatives were
affected by gastric cancer, and the age of onset of at least
one case was under 40 years. In other studies, a low fre-
quency of E-cadherin germline mutations in familial gastric
cancer has been reported [37,38]. The frequency of
E-cadherin germline mutations in breast cancer reported
thus far is low [17,18]. Mutations in E-cadherin reported in
lobular breast cancer cases are in most cases tumour
restricted, and are not germline alterations [5,19]. In the
17 gastric cancer families with germline mutations, five
members from three families were also affected by breast
cancer [13,17]. Three of these patients from three differ-
ent families had both breast and gastric cancer. One
patient had developed both lobular breast cancer and
diffuse-type gastric cancer [17]. In the other cases the
gastric cancers were of diffuse type, and the histology of
the breast tumours was unknown [13]. In one of these
families, two patients with breast cancer only were also
found; these cases were early-onset breast cancer.
In the present study, we did not find any pathogenic alter-
ations in 10 families with cases of breast, gastric or colon
cancer. We conclude that, although germline E-cadherin
mutations are sometimes found in familial gastric and
colon cancer, they are not frequently involved in families in
which breast cancer appears to segregate as a part of an
inherited predisposition for gastric and colon cancer.
Ala592Tyr alteration and breast cancer of ductal
comedo type
The frequency of Ala592Thr alteration, which was first
identified in one family with familial diffuse gastric, colon
and breast cancer (Fig. 1a), was almost the same in the dif-
ferent groups studied here (Table 2). In familial breast
cancer cases the frequency was 0.56% in non-
BRCA1/BRCA2 cases, and 0.79% in BRCA1 or BRCA2
carriers. In the sporadic cases and in the control popula-
tion, the frequencies were 0.83 and 0.80%, respectively.
This finding does not support an effect of this alteration in
predisposing to breast cancer in general. Thus, available
data thus far indicate that germline E-cadherin mutations
do not constitute a major risk factor for breast cancer.
However, it is quite clear that somatic alterations can have
an impact on the phenotype in lobular breast cancer. The
fact that many breast cancer cases with the alteration
(Ala592Thr) in the present study were of the ductal comedo
type may indicate a genetic basis for the phenotypic diver-
gence caused by this germline E-cadherin alteration.
Although lobular breast carcinoma and ductal breast carci-
noma of comedo type differ in many respects histologically,
both lack formation of more differentiated mammary gland
structures such as tubules. In lobular cancer, the cell char-
acteristically grows in thin single-cell files (so-called Indian
files). The comedo cancer is a poorly differentiated ductal
cancer, which is rich in mitoses, often with large intraductal
masses of cells with central necroses (comedons). Neither
of these cancers carry a good prognosis, but individual
prognosis with breast cancer is assessed mainly by
grading rather than by histological type [20,21].
Correlation between loss of heterozygosity at 16q,
tumourigenesis and metastasis in breast cancer
If E-cadherin functions as a classical tumour suppressor
gene, then loss or inactivation of the remaining normal
E-cadherin allele would be an important event in tumouri-
genesis in individuals who carry a germline mutation. In
tumours with somatic E-cadherin mutations, there is often
evidence of deletion of the wild-type E-cadherin allele
[19], whereas in cases with germline mutations in the
E-cadherin gene this is not usually seen [13,15,17]. We
did not find any germline mutations in the 19 familial
breast cancer cases with LOH at 16q studied here, which
indicates that E-cadherin does not act as a predisposing
factor for breast cancer in these families. In order to
examine whether somatic alterations in this gene are
involved in the carcinogenesis of these tumours, we
screened for somatic mutations in nine available tumours
from these cases, and we found one somatic mutation in
one of the lobular cancer cases. In cases with no mutation
in  E-cadherin, however, inactivation of this gene could
have been achieved by a variety of other mechanisms.
Genetic alterations in any component of the
cadherin–catenin complex appear to induce loss of adhe-
sion function [39,40]. Furthermore, epigenetic changes
such as promoter region hypermethylation, post-transcrip-
tional alteration and aberrant phosphorylation of members
of the cadherin–catenin complex can dysregulate E-cad-
herin function [41–44]. It is also possible that other
gene(s) located at 16q are altered, rather than E-cadherin.
Conclusion
This present study, together with previously reported data,
suggests that a germline mutation in E-cadherin is not a
major risk factor for breast cancer. However, germline, and
more often somatic mutations in this gene probably have
an impact on phenotypic divergence and prognosis, includ-
ing growth patterns of tumours, such as in lobular and
perhaps ductal comedo breast cancers. In addition, other
genetic alterations or epigenetic events at the E-cadherin
gene may have an impact on the metastatic behaviour of
the cancer cells, and thereby on the clinical outcome.
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